US OptionsDetailed Quotes
PBYI241220P2500
- 0.06
- 0.000.00%
15min DelayTrading Nov 22 12:23 ET
0.00High0.00Low
0.00Open0.06Pre Close0 Volume195 Open Interest2.50Strike Price0.00Turnover88.20%IV20.52%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.1496Delta0.3339Gamma51.17Leverage Ratio-0.0033Theta-0.0003Rho-7.65Eff Leverage0.0018Vega
Puma Biotechnology Stock Discussion
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Investing in PBYI carries a moderate risk level, reflected by its score of 6. The stock's positive recent earnings and profitable status provide a cushioning effect against volatility. However, the absence of proximity to its 52-week high and the moderately rated catalyst confers some uncertainty. Despite being in the biotechnology sector, which can be unpredictable, the company's strong financials and current trading metrics enhance its appeal. The moderately low...
it was always a diamond studded cougar 😉
and sometimes you have to embrace the fear and ride with it 😆
$Puma Biotechnology (PBYI.US)$
its a diamond studded cougar!
$Puma Biotechnology (PBYI.US)$
Ready Karen? You gotta learn to ride with the fear 🐆
$Puma Biotechnology (PBYI.US)$
$Puma Biotechnology (PBYI.US)$
No comment yet